RxDoctor Payments Data

Gloria Sam, MD

Family Medicine · Fayetteville, ARNPI 1366854614

Payments from drug & device makers

$444in general payments, 2019–2025

Across 10 payments — averaging $44.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$132
  • Amgen$122
  • AstraZeneca$84
  • Pfizer$31
  • Lilly USA, LLC$23
  • Astellas Pharma US Inc$21
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$43498%
  • Education$102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$444 in reported general payments places this provider in the 45th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$11,903
Medicare patients
56
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate60$100,599
OzempicSemaglutide45$90,074
FarxigaDapagliflozin Propanediol49$59,302
JardianceEmpagliflozin15$22,867
MounjaroTirzepatide11$11,797
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$9,288
Novolog FlexpenInsulin Aspart15$5,763
LantusInsulin Glargine,hum.Rec.Anlog11$3,037
Atorvastatin Calcium437$2,718
Pregabalin30$2,037
Omeprazole79$1,542
Gabapentin73$1,523
Losartan Potassium190$1,403
Metformin Hcl235$1,350
Lisinopril220$1,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$20$100,59960 claims
Novo NordiskOzempic$132$90,07445 claims
AstraZenecaFarxiga$84$59,30249 claims
Lilly USA, LLCMounjaro$23$11,79711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →